Posts

Ascidian and Lilly Ink Up‑to‑$1.9B Pact for RNA Exon Editing in Genetic Kidney Diseases

Ascidian Therapeutics and Eli Lilly have entered a global research collaboration to develop RNA exon editors for inherited kidney diseases, with deal value of up to $1.9 billion for Ascidian, including potential milestones and royalties. Lilly gains exclusive rights to use Ascidian’s RNA exon‑editing platform against certain undisclosed monogenic kidney disease targets, expanding its genetic‑medicines portfolio. The collaboration will combine Ascidian’s exon‑editing product engine with Lilly’s leadership in genetic medicines and could be expanded to additional targets beyond the initial kidney‑disease programs. Ascidian’s RNA exon‑editing platform removes or bypasses disease‑causing exons from mRNA, avoiding production of malformed proteins, and is already being explored in other therapeutic areas such as neurology and oncology. Sources: Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration ... Approach - Ascidian Therapeutics Ascidian and Lilly Enter Global Re...

Akeso takes center stage at ASCO 2026 as China biotech cements its global arrival

Eli Lilly’s ultimatum to hospitals: Send 340B claims data by June 8 or lose discounts

Gilead highlights Tubulis ADC ovarian cancer data as validation of buyout decision

Revolution Medicines Confident in RAS Leadership as Rivals Square Up: Recent News Summary (June 2026)

ASCO26: AstraZeneca unveils data it hopes will persuade FDA to approve oral SERD

Travere pays Everest $112.5M upfront to grow rare kidney disease pipeline

Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027

KOL Views Q&A: Prostate cancer at ASCO 2026—detailed looks at upstream data for J&J's Erleada, Pfizer's Talzenna

FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Itovebi (Inavolisib) in HR‑Positive, HER2‑Negative Breast Cancer with PIK3CA Mutation

Obesity care startup Ilant Health raises $15M Series A for AI‑supported precision‑obesity‑care platform

Abivax stock falls on cancer cases despite strong ulcerative colitis phase 3 data

Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks